Suven Life Sciences Initiates Phase 1 Clinical Trial And First Dosing Of SUVN-911


Suven Life Sciences initiated their NCESUVN-911, a potent, selective, brain penetrant and orally active, novel chemical entity intended for the treatment of major depressive disorder (MDD) has initiated Phase 1 development and first dosing under US IND 133850

SUVN-911 a neuronal nicotinic alpha-4-beta-2 receptor, a unique class of protein is expressed at high level in brain. It regulates vital biological functions that are impaired in Major Depressive Disorders (MDD).

Preclinical studies in animal models suggest that SUVN-911 has a faster onset of action, unlike the conventional antidepressants. In addition it is also devoid of sexual side effects and also improves the cognitive skills which are the major side effects of current anti-depressant therapy.

SUVN-911 has completed all the preclinical, safety, early tox and GLP tox studies.

Suven life science submitted Investigational New Drug Application (IND) to conduct Phase 1 clinical trial for MDD, under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA, USA).

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717  
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: